Over 500 participants from 46 countries attended TAT 2013 in Paris, March 4-6, 2013, with 60 plenary lectures, presented by leading experts in clinical cancer research and oncology drug development:
- NDDO Honorary Award Lecture 2013 by Jean-Pierre Armand: “Phase 1, a critical step for cancer drug development”
- Keynote Lecture by Michael B. Atkins: “Targeting immune checkpoints in cancer therapy”
- New immune checkpoints as targets: updates on four major drug development programs
- Metabolic drug targets: updates on three major drug development programs
- Drug targeting the RAS-RAF-MEK pathway: drugs for BRAF-, KRAS-mutant tumors, drug combinations involving MEK inhibition
- Design and development of immunoconjugates and TLRLigand-long peptide conjugates
- Phase 1 studies, completed or in progress: including new data never presented before
- Whole-genome sequencing in patient selection for targeted therapies
- Preclinical models in drug discovery and development
- Collaborative phase 1 trials by small biotech and academia: recent examples and future perspectives
TO VIEW TAT 2013 PRESENTATIONS, CLICK "PROGRAM" IN THE LEFT-HAND MENU.
Don't miss future updates and keep following "the number one in phase 1" via Twitter, LinkedIn and Facebook.
